Visible science

Nicox develops innovative therapeutics to help maintain vision and improve ocular health

Watch

Learn more about the mechanism of action of NCX 470, our lead product candidate in glaucoma

Nicox Provides Second Quarter 2024 Update
July 18, 2024 Read more
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
July 16th, 2024 Read more
Nicox announces the success of its equity offering with preemptive rights through an issue of stock with warrants, for a total amount of €3.3 million, extending its cash runway to continue the development of NCX 470
June 19, 2024 Read more